Douma LH, Lalezari F, van der Noort V, de Vries JF, et al. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol 2023;24:1219-1228.
PMID: 37844598